Piper Jaffray is out with its report today on MAKO Surgical MAKO, reiterating Overweight.
In its report, Piper Jaffray writes, "We continue to view MAKO's surgical robotic arm as one of the most compelling innovations in orthopaedics in recent years. We reiterate our Overweight rating on MAKO and view the stock as attractive at current levels."
At the time of posting, shares of MAKO were trading pre-market at $33.00, up 1.23% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in